Kyle Faget Authors Article on Considerations for Mobile Health Technology Developers
September 28, 2022
pharmaphorum
Foley & Lardner LLP Partner Kyle Faget authored the article, “Considerations for Mobile Health Technology Developers: Part 1,” published by pharmaphorum, about the U.S. Food and Drug Administration (FDA)’s common approach to regulating mHealth products, general wellness devices, and mobile medical applications.
Faget says, “Although mHealth has been gaining in popularity for at least the past decade, before commercializing their mHealth products, developers must determine whether the product is subject to (FDA) regulation as a medical device. If so, developers must develop and execute on a regulatory strategy.”
Part 2 of this series will be devoted to clinical decision support (CDS) software.
Related News
June 12, 2026
In the News
Chris Babcock and Chris Converse on Wave of Companies Moving to Texas
Foley & Lardner LLP partners Chrisopher Babcock and Chris Converse commented on the widening trend of companies reincorporating to Texas in the Houston Business Journal article, “Texas law changes could spark wave of corporate redomestication proposals."
June 10, 2026
In the News
Louis Lehot and Patrick Daugherty Publish on Revitalizing IPO Markets
Foley & Lardner LLP partners Louis Lehot and Patrick Daugherty authored the Westlaw Today article, How to Make IPOs Great Again, analyzing SEC public market reform proposals.
June 9, 2026
In the News
Foley's Chicago Growth, Partner Additions Garner Widespread Media Coverage
Foley & Lardner LLP attorneys Melissa McGrory, Teresa Napoli, and Madeline Clasen are highlighted across the media for their recent arrival to the firm's Chicago office.